Citation Impact
Citing Papers
Active learning increases student performance in science, engineering, and mathematics
2014 Standout
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
2009
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
2007 Nature
Targeting HER proteins in cancer therapy and the role of the non-target HER3
2007
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
2007
Antitumor activity of HER-2 inhibitors
2004
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Statistical analysis of microsatellite DNA data
1999
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
2012
Gastric cancer
2016 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
2014
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Comparative genomics of the environmental stress response in ascomycete fungi
2007
Linking class-switch recombination with somatic hypermutation
2001 StandoutNobel
Proteasome inhibitors in cancer therapy
2017
An Acquired and Endogenous Glycocalyx Forms a Bidirectional “Don’t Eat” and “Don’t Eat Me” Barrier to Phagocytosis
2020 StandoutNobel
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
2014
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
2016
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
2007 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
2006
Cancer drug resistance: an evolving paradigm
2013 Standout
A role for mitochondria in NLRP3 inflammasome activation
2010 StandoutNature
Epidermal Growth Factor Receptor Targeting in Cancer
2006
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent
2011
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
2007
Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
2014
Nasopharyngeal carcinoma
2019 Standout
Triptans in Migraine
2000
Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
2006
Intra-Deme Molecular Diversity in Spatially Expanding Populations
2003
Hydrogen Peroxide Sensing and Signaling
2007
Lymphocyte responses and cytokines
1994 Standout
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Detecting the number of clusters of individuals using the software structure : a simulation study
2005 Standout
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
2007
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
2012
Modulation of Ocular Surface Glycocalyx Barrier Function by a Galectin-3 N-terminal Deletion Mutant and Membrane-Anchored Synthetic Glycopolymers
2013 StandoutNobel
CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM
1993 Nature
Genetic diversity and introgression in the Scottish wildcat
2001
β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
2007 StandoutNobel
Integration of EGFR inhibitors with radiochemotherapy
2006
Microbial chemical signaling: a current perspective
2012
AKT/PKB Signaling: Navigating the Network
2017 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
The PI3K Pathway in Human Disease
2017 Standout
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Cervical cancer
2019 Standout
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme
2000 StandoutNobel
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
2015
Interactions of fungal pathogens with phagocytes
2016
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
2007 Standout
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Triptans and CNS Side-Effects
2004
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis
2016 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Improved Learning in a Large-Enrollment Physics Class
2011 StandoutScienceNobel
Increasing intracellular trehalose is sufficient to confer desiccation tolerance to Saccharomyces cerevisiae
2015 StandoutNobel
The Hitchhiker’s Guide to Flow Chemistry
2017 Standout
Marine Indole Alkaloids: Potential New Drug Leads for the Control of Depression and Anxiety
2010 Standout
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
2010
Detecting rare introgression of domestic dog genes into wild wolf (Canis lupus) populations by Bayesian admixture analyses of microsatellite variation
2002
Arlequin (version 3.0): an integrated software package for population genetics data analysis.
2007 Standout
Increased T Cell Autoreactivity in the Absence of CD40-CD40 Ligand Interactions: A Role of CD40 in Regulatory T Cell Development
2001 StandoutNobel
2004 Standout
Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death
2012
The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition
2014 Standout
REACTIVE OXYGEN SPECIES: Metabolism, Oxidative Stress, and Signal Transduction
2004 Standout
Inference of Population Structure Using Multilocus Genotype Data: Linked Loci and Correlated Allele Frequencies
2003 Standout
Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
2010
Adjuvant Therapy in Patients With Resected Poor-Risk Head and Neck Cancer
2006
Global Transcriptional Responses of Fission Yeast to Environmental Stress
2003
Does Active Learning Work? A Review of the Research
2004 Standout
Full of Sound and Fury: History of Ancient DNA
1999
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
Widespread Origins of Domestic Horse Lineages
2001 StandoutScience
Unraveling Function in the TNF Ligand and Receptor Families
1994 StandoutScienceNobel
Assessing Allelic Dropout and Genotype Reliability Using Maximum Likelihood
2002
Works of Deborah A. Smith being referenced
A Conserved Stress-activated Protein Kinase Regulates a Core Stress Response in the Human Pathogen Candida albicans
2004
A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
2009
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
2005
Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
2005
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
2007
Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects
2009
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects
2004
The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers
1998
Transcriptional diversity at the duplicated human CD8β loci
1993
The Srk1 Protein Kinase Is a Target for the Sty1 Stress-activated MAPK in Fission Yeast
2002
Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
2015
Ybp1 and Gpx3 Signaling in Candida albicans Govern Hydrogen Peroxide-Induced Oxidation of the Cap1 Transcription Factor and Macrophage Escape
2013
Mechanisms Underlying the Exquisite Sensitivity of Candida albicans to Combinatorial Cationic and Oxidative Stress That Enhances the Potent Fungicidal Activity of Phagocytes
2014
Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies
2007
Is incest common in gray wolf packs?
1997
Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study
2011
Thioredoxin Regulates Multiple Hydrogen Peroxide-Induced Signaling Pathways in Candida albicans
2010
A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors
2004
Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
2008
Molecular Genetics of Pre‐1940 Red Wolves
1996
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
2014
Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.
2011
Clinical activity of GW572016 in EGF10003 in patients with solid tumors
2004
Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia
2009
The pausing principle: Increasing the efficiency of memory for ongoing events
1979
Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors
2007
Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors.
2013
A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors
2004
Clinical activity of GW572016 in EGF10003 in patients with solid tumors
2004
Role of the Hog1 Stress-activated Protein Kinase in the Global Transcriptional Response to Stress in the Fungal PathogenCandida albicans
2005
Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826).
2011
The Use of Microsatellite Variation to Infer Population Structure and Demographic History in a Natural Model System
1999